Neuralstem, Inc. CUR announced that Jonathan D. Glass, MD, site investigator at Emory
University, presented long-term follow up data on the Phase I trial testing
NSI-566 human neural stem cells in the treatment of amyotrophic lateral
sclerosis (ALS or Lou Gehrig's disease). The presentation, which occurred at
the Annual Symposium on ALS of the Foundation Andre-Delambre, in Montreal,
Canada, on Friday, and was not open to the public, covered data up to
approximately 1200 days post the stem cell treatment.
Dr. Glass reported that patients in the last safety cohort (n=3), who received
treatments in both the lumbar and the cervical region with the highest number
of cells per injection, all showed significant slowing of the progression of
the disease. One patient showed functional improvement from pre-treatment
baseline, which is maintained to present day. The other two patients are
maintaining the same level of functionality as they had at the baseline for
over three years since the stem cell treatment.
"The long-term follow up data is very encouraging," said Karl Johe, PhD,
Neuralstem's Chairman and Chief Scientific Officer. "In Phase I, patients 10,
11, and 12 each received 10 lumbar and five cervical injections, of 100,000
cells each, which was far below the safe maximal dose. Even so, the data shows
a significant slowing of the disease progression for over three years. If
replicated on a larger scale, this could represent meaningful improvement in
quality of life, and lifespan, compared to untreated patients. In our Phase
II dose escalation trial, we successfully reached the maximal dose planned,
which consisted of 20 lumbar and 20 cervical injections of 400,000 cells
each, more than ten times the number of stem cells delivered in the highest
dose cohort of the Phase I trial."
"The progress in this trial is truly groundbreaking," said Dr. Glass, who is
Director of the Emory ALS Center at Emory University, the first site in the
trial. "It has provided data on the safety of multiple injections and multiple
transplantation surgeries in ALS patients, as well as the long- term survival
of the transplanted cells in the human spinal cord. This provides a strong
foundation for moving ahead with more definitive trials focused on the
potential therapeutic efficacy of spinal cord transplantation of neural stem
cells for ALS."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in